Reynders McVeigh Capital Management LLC Has $2.88 Million Holdings in Merck & Co., Inc. (NYSE:MRK)

Reynders McVeigh Capital Management LLC trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 6.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,007 shares of the company’s stock after selling 3,350 shares during the quarter. Reynders McVeigh Capital Management LLC’s holdings in Merck & Co., Inc. were worth $2,882,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in MRK. Krilogy Financial LLC increased its stake in shares of Merck & Co., Inc. by 0.4% during the second quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock valued at $201,000 after buying an additional 11 shares during the period. Balentine LLC increased its stake in shares of Merck & Co., Inc. by 1.0% during the second quarter. Balentine LLC now owns 2,107 shares of the company’s stock valued at $135,000 after buying an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. increased its stake in shares of Merck & Co., Inc. by 0.4% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 9,291 shares of the company’s stock valued at $595,000 after buying an additional 39 shares during the period. Thompson Davis & CO. Inc. increased its stake in shares of Merck & Co., Inc. by 0.9% during the second quarter. Thompson Davis & CO. Inc. now owns 4,313 shares of the company’s stock valued at $276,000 after buying an additional 40 shares during the period. Finally, Weatherly Asset Management L. P. increased its stake in shares of Merck & Co., Inc. by 0.6% during the second quarter. Weatherly Asset Management L. P. now owns 7,426 shares of the company’s stock valued at $476,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 72.85% of the company’s stock.

Shares of Merck & Co., Inc. (NYSE:MRK) opened at $55.45 on Tuesday. Merck & Co., Inc. has a 52 week low of $53.36 and a 52 week high of $66.80. The firm has a market capitalization of $151,020.00, a PE ratio of 59.62, a PEG ratio of 2.46 and a beta of 0.75. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.04. Merck & Co., Inc. had a return on equity of 27.73% and a net margin of 6.40%. The business had revenue of $10.43 billion for the quarter, compared to analyst estimates of $10.48 billion. During the same quarter in the previous year, the firm earned $0.89 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis. research analysts forecast that Merck & Co., Inc. will post 4.15 EPS for the current fiscal year.

Merck & Co., Inc. announced that its board has approved a share buyback program on Tuesday, November 28th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the company to buy shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

The company also recently announced a quarterly dividend, which will be paid on Friday, April 6th. Investors of record on Thursday, March 15th will be issued a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.46%. The ex-dividend date is Wednesday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 206.45%.

In related news, Director Wendell P. Weeks sold 5,000 shares of Merck & Co., Inc. stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $53.57, for a total transaction of $267,850.00. Following the completion of the sale, the director now owns 5,100 shares of the company’s stock, valued at $273,207. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Weir Mirian M. Graddick sold 60,000 shares of Merck & Co., Inc. stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $61.63, for a total value of $3,697,800.00. Following the sale, the insider now directly owns 101,484 shares of the company’s stock, valued at approximately $6,254,458.92. The disclosure for this sale can be found here. Insiders have sold 82,500 shares of company stock valued at $5,026,025 in the last ninety days. Corporate insiders own 0.25% of the company’s stock.

MRK has been the topic of several research reports. JPMorgan Chase & Co. set a $70.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Sunday, October 29th. BMO Capital Markets set a $70.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Wednesday, October 18th. Citigroup upgraded Merck & Co., Inc. from a “neutral” rating to a “buy” rating and set a $72.00 price target on the stock in a research note on Wednesday, October 18th. UBS Group cut their target price on Merck & Co., Inc. from $72.00 to $67.00 and set a “buy” rating on the stock in a research note on Monday, October 30th. Finally, Sanford C. Bernstein reiterated a “buy” rating and issued a $64.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, November 15th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $66.88.

WARNING: “Reynders McVeigh Capital Management LLC Has $2.88 Million Holdings in Merck & Co., Inc. (NYSE:MRK)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/13/reynders-mcveigh-capital-management-llc-sells-3350-shares-of-merck-co-inc-mrk.html.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply